Lonza

Company Overview

Lonza is a biotechnology company that helps pharmaceutical, biotech and nutrition companies bring their treatments to the market. The company operates in four segments: Small Molecules, Biologics, Cell and gene, and Capsules and health Ingredients.

The Cell & Gene division includes three business areas: Cell & Gene Technologies, Personalized Medicine, and Bioscience. Cell & Gene Technologies (CGT) is focused on providing an integrated range of CDMO services that span the complete value chain of cell and gene therapy modalities (allogeneic and autologous therapies and viral vectors). CDMO services include 2D/3D cell culture and the latest exosome development and manufacturing technologies.

Financial Highlights (FY 2025)

Company's Business Segments

• Integrated Biologics : This segment helps to accelerate and de-risk the path to market with best-in-class, end-to-end offerings from clinical development to drug substance and drug product manufacturing. It also comprises two Technology Platforms: Mammalian and Drug Product.
• Advanced Synthesis : This segment comprises two technology platforms such as bioconjugates and small molecules leveraging new and established modalities to enable advanced therapies for its customers and their patients.
• Specialized Modalities : This segment provides comprehensive solutions that facilitate the accelerated development, manufacturing, and commercialization of life-changing treatments.